Although AKT itself is rarely mutated in AML, the kinase lies at the confluence of several signaling pathways in which various components can themselves be activated by gene mutations (e.g. FLT3, KIT, NRAS, KRAS, PIK3CB...). This evidence concerns the gene AKT1 and acute myeloid leukemia.